
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    1. Key functional markers and pathways<br><br>I‚Äôll first group the most informative genes by function, focusing on what they imply about cell state and lineage.<br><br>**a. Inflammatory / cytokine / immune-response‚Äìrelated genes**<br><br>- **IL6, IL20** ‚Äì Pro‚Äëinflammatory cytokines; IL6 is a classic NF‚ÄëŒ∫B/STAT3‚Äëinducible cytokine, often upregulated in reactive glia and inflamed endothelium; IL20 is also associated with inflammatory signaling.<br>- **CCL2** ‚Äì Potent chemokine (MCP‚Äë1) that recruits monocytes; strongly induced in inflammatory contexts, including reactive astrocytes and endothelial cells under cytokine stimulation.<br>- **IRF1, NFKBIZ** ‚Äì Transcription factors in interferon/NF‚ÄëŒ∫B pathways; mark cells under inflammatory/immune activation.<br>- **ICAM1, ICAM4, ICAM5** ‚Äì Intercellular adhesion molecules:<br>  - **ICAM1**: classic endothelial/immune adhesion receptor, strongly induced by TNF/IL1.<br>  - **ICAM4**: more typical of erythroid lineage, but low-level or ambient expression can appear in vascular/immune contexts.<br>  - **ICAM5 (telencephalin)**: neuronally enriched adhesion molecule, especially in telencephalic neurons, but can appear in some vascular/perivascular populations in scRNA‚Äëseq due to ambient RNA or low expression.<br>- **S100P** ‚Äì Calcium‚Äëbinding protein; often induced in inflammation, epithelial activation, and some reactive states.<br><br>These collectively indicate a **strong inflammatory/immune-activated state**, not a quiescent neural cell.<br><br>**b. Extracellular matrix (ECM), matrix remodeling, and secreted factors**<br><br>- **SFRP2** ‚Äì Secreted Wnt pathway modulator; often expressed by perivascular fibroblast‚Äëlike cells, stromal cells, and some endothelial/perivascular populations.<br>- **FBLN1 (Fibulin‚Äë1)** ‚Äì ECM glycoprotein; enriched in vascular/mesenchymal ECM, including perivascular fibroblasts and endothelial-associated matrix.<br>- **DCN (Decorin)** ‚Äì Small leucine-rich proteoglycan; canonical fibroblast/perivascular ECM marker, also in meningeal/perivascular stromal cells.<br>- **EGFL6** ‚Äì Secreted EGF‚Äëlike protein; strongly associated with vasculature, angiogenesis, and perivascular stromal cells.<br>- **CEMIP (KIAA1199)** ‚Äì Hyaluronan-binding protein involved in ECM remodeling and cell migration; often upregulated in stromal/vascular cells and in inflammation.<br>- **HAS1** ‚Äì Hyaluronan synthase 1; ECM glycosaminoglycan synthesis, typical of fibroblast‚Äëlike and stromal cells.<br>- **CLU (Clusterin)** ‚Äì Secreted chaperone; abundant in astrocytes and also in vascular/stromal cells; upregulated in stress and neurodegeneration.<br>- **IGFBP2, IGFBP5** ‚Äì Insulin‚Äëlike growth factor binding proteins; secreted factors modulating IGF signaling, often in astrocytes, oligodendrocyte lineage, and vascular/stromal cells.<br>- **APOE** ‚Äì Lipoprotein; high in astrocytes and microglia, but also in perivascular cells and reactive states.<br>- **CPE (Carboxypeptidase E)** ‚Äì Secretory pathway enzyme; in neurons and endocrine cells, but also in some glial/vascular secretory phenotypes.<br><br>This ECM/secreted profile is **strongly perivascular/fibroblast‚Äëlike**, with some overlap with astrocytic secretory programs.<br><br>**c. Vascular / perivascular / barrier-related**<br><br>- **LEPR (Leptin receptor)** ‚Äì Expressed in hypothalamic neurons but also in **endothelial and perivascular cells** in brain; in human scRNA‚Äëseq, LEPR+ perivascular fibroblast‚Äëlike cells and some endothelial subsets are well described.<br>- **SLC26A2** ‚Äì Sulfate transporter; expressed in chondrocytes and some fibroblast‚Äëlike cells; in brain, tends to appear in perivascular/meningeal stromal populations.<br>- **SLC6A20** ‚Äì Proline/imidazole transporter; enriched in endothelial and barrier-associated cells in several tissues.<br>- **EGFL6, FBLN1, DCN, HAS1, CEMIP** (as above) ‚Äì All strongly point to a **vascular-associated stromal ECM** program.<br>- **ICAM1, CCL2, IL6** ‚Äì Classic markers of **activated endothelium** and perivascular cells under inflammatory stimulation.<br><br>These together are highly characteristic of **perivascular fibroblast / vascular leptomeningeal cell (VLMC)‚Äìlike populations** in human brain scRNA‚Äëseq atlases.<br><br>**d. Transcription factors / developmental regulators**<br><br>- **FOXP2** ‚Äì Forkhead TF; canonical in specific neuronal subtypes (e.g., corticothalamic projection neurons, striatal MSNs), but low-level expression can appear in some non-neuronal clusters in human data (often low and not functionally defining). Its presence here, without a strong neuronal program, is likely not lineage-defining.<br>- **EGR4** ‚Äì Immediate early gene; activity-dependent TF, can be induced by stress/inflammation.<br>- **BTG2** ‚Äì Immediate early/growth arrest gene; broadly induced by stress, not lineage-specific.<br>- **MEG3** ‚Äì lncRNA; enriched in neurons and some glia, but also in perivascular cells in some datasets.<br><br>These suggest an **activated/stressed state**, not a specific neuronal lineage.<br><br>**e. Ion channels / neurotransmission-related**<br><br>- **KCNMA1** ‚Äì BK large-conductance Ca2+-activated K+ channel; expressed in neurons, smooth muscle, and some endothelial/perivascular cells.<br>- **CHRNA6, CHRNB3** ‚Äì Nicotinic acetylcholine receptor subunits; strongly enriched in dopaminergic neurons (e.g., midbrain) and some striatal neurons, but here they appear without a broader neuronal synaptic program, suggesting low-level/ambient or non-defining expression.<br><br>Given the absence of core neuronal markers (e.g., SNAP25, SYT1, RBFOX3/NEUN, MAP2, SLC17A7, GAD1/2), these ion channel/receptor genes are unlikely to indicate a neuronal identity.<br><br>**f. Metabolic / stress / hypoxia-related**<br><br>- **ANKRD37** ‚Äì Strongly hypoxia-inducible gene (HIF target); marks cells under low oxygen or pseudo-hypoxic signaling.<br>- **CRYM** ‚Äì Thyroid hormone‚Äìbinding protein; expressed in some neurons and glia, but also in stromal cells; often associated with metabolic regulation.<br>- **GSTM5** ‚Äì Glutathione S-transferase; detoxification, oxidative stress response.<br>- **NFKBIZ, IRF1, BTG2** ‚Äì As above, stress/inflammatory transcriptional response.<br><br>This supports a **stressed, possibly hypoxia/inflammation-exposed perivascular environment**.<br><br>**g. Miscellaneous / structural / others**<br><br>- **HPR (Haptoglobin-related protein)** ‚Äì Plasma protein; can appear in vascular-associated cells or due to blood contamination; consistent with vascular proximity.<br>- **PDZK1IP1** ‚Äì PDZK1-interacting protein; often in epithelial/vascular cells.<br>- **ADIRF** ‚Äì Adipogenesis regulatory factor; appears in fibroblast-like and perivascular stromal cells.<br>- **FAM107A** ‚Äì Tumor suppressor; enriched in some glial and perivascular populations.<br>- **VPS13D, RNF212, ACTRT3** ‚Äì More generic cellular function genes, not strongly lineage-defining.<br><br>Overall, the functional profile is **ECM-rich, inflammatory, perivascular/vascular-associated, fibroblast-like**, with no coherent neuronal or classic astrocyte/microglia/oligodendrocyte core program.<br><br>---<br><br>2. Key cell-type‚Äìassociated markers<br><br>Now focusing on markers that are particularly informative for brain cell types:<br><br>**Markers supporting perivascular fibroblast / VLMC / meningeal stromal identity**<br><br>- **DCN, FBLN1, HAS1, EGFL6, CEMIP, SFRP2, ADIRF** ‚Äì This combination is highly characteristic of **perivascular fibroblast / vascular leptomeningeal cell (VLMC)** clusters in human and mouse brain scRNA‚Äëseq (e.g., Zeisel et al. 2018; Vanlandewijck et al. 2018; Hodge et al. 2019; human VLMC-like clusters in multiple atlases).<br>- **LEPR** ‚Äì Reported in perivascular fibroblast-like cells and some endothelial subsets in human brain; also in hypothalamic neurons, but here the rest of the profile is non-neuronal.<br>- **SLC26A2, SLC6A20** ‚Äì Transporters enriched in barrier/vascular/perivascular stromal cells.<br>- **ICAM1, CCL2, IL6** ‚Äì Strongly expressed by **activated endothelium and perivascular stromal cells** under inflammatory conditions.<br>- **HPR** ‚Äì Blood/vascular-associated; consistent with vascular adjacency.<br><br>**Markers that might suggest astrocyte-like features but are not dominant**<br><br>- **CLU, APOE, IGFBP2, IGFBP5, CPE** ‚Äì These are seen in astrocytes and reactive astrocytes, but also in perivascular fibroblast-like cells. The absence of strong astrocyte core markers (e.g., AQP4, GFAP, SLC1A2, SLC1A3, ALDH1L1) argues against a primary astrocyte identity.<br><br>**Markers that might suggest neuronal features but are not supported by the rest of the profile**<br><br>- **ICAM5, FOXP2, CHRNA6, CHRNB3, KCNMA1, CRYM, MEG3** ‚Äì All can be neuronal, but:<br>  - No canonical neuronal markers (SNAP25, SYT1, RBFOX3, MAP2, NEFL/M/H, SLC17A7, GAD1/2, etc.).<br>  - Strong ECM and inflammatory signature is atypical for neurons.<br>  - In human scRNA‚Äëseq, low-level neuronal transcripts often appear in perivascular clusters due to ambient RNA or doublets; but the dominant program here is clearly non-neuronal.<br><br>**Markers that might suggest microglia/immune but are incomplete**<br><br>- **IRF1, NFKBIZ, CCL2, IL6** ‚Äì Inflammatory, but:<br>  - No P2RY12, CX3CR1, TMEM119, AIF1/IBA1, CSF1R, etc.<br>  - Strong ECM/fibroblast signature is not typical of microglia.<br><br>**Markers that might suggest endothelial but are incomplete**<br><br>- **ICAM1, CCL2, IL6, HPR, PDZK1IP1** ‚Äì Endothelial activation markers, but:<br>  - No strong endothelial core markers (PECAM1/CD31, VWF, KDR/VEGFR2, CLDN5, RGS5, etc.).<br>  - ECM profile (DCN, FBLN1, HAS1, EGFL6) is more fibroblast-like than endothelial.<br><br>Thus, the **most coherent cell-type signature** is **perivascular fibroblast / VLMC / meningeal stromal cell**, in an **inflammatory/reactive state**.<br><br>---<br><br>3. Cross-referencing with scRNA‚Äëseq databases and literature<br><br>Cross-checking this marker combination with known atlases:<br><br>- **Mouse brain (Zeisel et al., Cell 2018; Tasic et al.)**:<br>  - VLMC/perivascular fibroblast clusters show high **DCN, COL1A1/2, FBLN1, SFRP2, EGFL6, CEMIP, HAS1**, and other ECM genes.<br>  - They are distinct from endothelial (CLDN5+, PECAM1+) and from astrocytes (AQP4+, GFAP+, SLC1A2+).<br><br>- **Mouse brain vasculature (Vanlandewijck et al., Nature 2018)**:<br>  - Perivascular fibroblast populations express **DCN, FBLN1, SFRP2, EGFL6, CEMIP**, and other ECM genes, with inflammatory inducible genes under stress.<br><br>- **Human brain atlases (Hodge et al. 2019; Lake et al.; multiple recent human cortex datasets)**:<br>  - ‚ÄúVLMC‚Äù or ‚Äúperivascular fibroblast‚Äù clusters show:<br>    - High **DCN, FBLN1, SFRP2, EGFL6, CEMIP, COL1A1/2, LUM**, etc.<br>    - Often **LEPR** and other stromal markers.<br>    - Under disease/inflammation, upregulate **CCL2, IL6, ICAM1**, and other NF‚ÄëŒ∫B/IRF1 targets.<br><br>- **CellMarker / PanglaoDB / Azimuth references**:<br>  - **DCN, FBLN1, SFRP2, EGFL6, CEMIP, HAS1** are annotated as **fibroblast / perivascular stromal / VLMC** markers in brain and other tissues.<br>  - **LEPR** is annotated in perivascular stromal and endothelial subsets in brain.<br><br>The **exact combination** of **DCN+ FBLN1+ SFRP2+ EGFL6+ CEMIP+ HAS1+ LEPR+ CCL2+ IL6+ ICAM1+** is highly characteristic of **perivascular fibroblast / VLMC** clusters in human brain scRNA‚Äëseq, particularly under inflammatory or disease conditions.<br><br>---<br><br>4. Most probable general cell type<br><br>Given:<br><br>- Strong ECM/fibroblast-like signature (DCN, FBLN1, HAS1, EGFL6, CEMIP, SFRP2, ADIRF).<br>- Vascular/perivascular association (LEPR, HPR, ICAM1, CCL2, IL6, SLC26A2, SLC6A20).<br>- Inflammatory activation (IL6, CCL2, IRF1, NFKBIZ, BTG2, ANKRD37).<br>- Absence of core neuronal, astrocytic, oligodendrocytic, or microglial marker sets.<br><br>The **most probable general cell type** is:<br><br>> **Perivascular stromal cell / fibroblast-like cell (VLMC-like) in brain vasculature.**<br><br>---<br><br>5. Top 3 most probable sub cell types (ranked)<br><br>Within this general category, I‚Äôll rank plausible subtypes:<br><br>### 1) Perivascular fibroblast / VLMC (vascular leptomeningeal cell) ‚Äì **most likely**<br><br>**Supporting markers:**<br><br>- **Core ECM/fibroblast markers**: DCN, FBLN1, HAS1, EGFL6, CEMIP, SFRP2, ADIRF.<br>- **Perivascular association**: LEPR, SLC26A2, SLC6A20, HPR.<br>- **Inflammatory activation**: IL6, CCL2, ICAM1, IRF1, NFKBIZ, ANKRD37.<br>- **Secreted factors**: IGFBP2, IGFBP5, CLU, APOE ‚Äì consistent with perivascular stromal secretome.<br><br>This matches well-described **VLMC/perivascular fibroblast clusters** in human cortex and other brain regions.<br><br>**Interpretation:**  <br>Most likely **perivascular fibroblast / VLMC**, in an **activated/inflammatory state** (e.g., disease, injury, or ex vivo stress).<br><br>---<br><br>### 2) Inflammatory/activated vascular endothelial-like cell ‚Äì **less likely**<br><br>**Supporting markers:**<br><br>- **ICAM1, CCL2, IL6, IRF1, NFKBIZ** ‚Äì classic of activated endothelium.<br>- **HPR, PDZK1IP1** ‚Äì vascular-associated.<br><br>**Against:**<br><br>- Lack of strong endothelial core markers (PECAM1, VWF, CLDN5, KDR, RGS5).<br>- Strong fibroblast ECM signature (DCN, FBLN1, HAS1, EGFL6, CEMIP, SFRP2) is atypical for pure endothelium.<br><br>Thus, an **endothelial identity** is possible but not well supported; if present, it would more likely be a **perivascular fibroblast‚Äìendothelial doublet** rather than a pure endothelial cluster.<br><br>---<br><br>### 3) Reactive astrocyte-like perivascular glial cell ‚Äì **least likely of the three, but plausible**<br><br>**Supporting markers:**<br><br>- **APOE, CLU, IGFBP2, IGFBP5, CPE** ‚Äì seen in astrocytes, especially reactive ones.<br>- **Inflammatory genes** (IL6, CCL2, IRF1, NFKBIZ) ‚Äì consistent with reactive astrocytes.<br><br>**Against:**<br><br>- Absence of canonical astrocyte markers (AQP4, GFAP, SLC1A2, SLC1A3, ALDH1L1).<br>- Strong fibroblast ECM signature (DCN, FBLN1, HAS1, EGFL6, CEMIP, SFRP2) is more typical of perivascular fibroblasts than astrocytes.<br><br>Thus, a **reactive astrocyte** identity is less likely than a **perivascular fibroblast** identity.<br><br>---<br><br>**Most likely subtype (final call)**<br><br>> **Perivascular fibroblast / vascular leptomeningeal cell (VLMC), inflammatory/reactive subtype.**<br><br>If you are assigning a label in a human brain scRNA‚Äëseq annotation, a concise label could be:<br><br>- ‚Äú**VLMC / perivascular fibroblast (IL6/CCL2+)**‚Äù  <br>or  <br>- ‚Äú**Perivascular fibroblast, inflammatory**‚Äù<br><br>depending on your ontology.<br><br>---<br><br>6. Concise summary<br><br>- The marker set is dominated by **ECM and fibroblast-like genes** (DCN, FBLN1, HAS1, EGFL6, CEMIP, SFRP2, ADIRF) and **perivascular/vascular-associated markers** (LEPR, SLC26A2, SLC6A20, HPR).<br>- There is a strong **inflammatory activation signature** (IL6, CCL2, ICAM1, IRF1, NFKBIZ, ANKRD37).<br>- Canonical neuronal, astrocytic, oligodendrocytic, and microglial core markers are absent.<br>- Cross-referencing with brain scRNA‚Äëseq atlases and CellMarker/PanglaoDB strongly supports a **perivascular fibroblast / VLMC** identity.<br>- The most probable annotation is **perivascular fibroblast / VLMC, inflammatory/reactive subtype**.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Perivascular stromal cell / fibroblast-like cell (VLMC-like) in brain vasculature</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Perivascular fibroblast / vascular leptomeningeal cell (VLMC), inflammatory/reactive subtype</li><li>Inflammatory/activated vascular endothelial-like cell</li><li>Reactive astrocyte-like perivascular glial cell</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Perivascular fibroblast‚Äìendothelial doublet</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">nan</div>
                        <div class="scoring-content">
                            Error: Error code: 400 - {'error': {'message': "Unsupported parameter: 'max_tokens' is not supported with this model. Use 'max_completion_tokens' instead.", 'type': 'invalid_request_error', 'param': 'max_tokens', 'code': 'unsupported_parameter'}}<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    